IGI Logo

SMS Pharmaceuticals is currently trading at Rs. 290.30, up by 16.30 points or 5.95% from its previous closing of Rs. 274.00 on the BSE.

The scrip opened at Rs. 279.10 and has touched a high and low of Rs. 297.25 and Rs. 279.05 respectively. So far 31782 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 329.00 on 10-Nov-2025 and a 52 week low of Rs. 175.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 297.25 and Rs. 270.80 respectively. The current market cap of the company is Rs. 2728.08 crore.

The promoters holding in the company stood at 68.07%, while Institutions and Non-Institutions held 3.16% and 28.78% respectively.

SMS Pharmaceuticals’ associate company -- VKT Pharma has received approval from US Food and Drug Administration (USFDA) for reformulated Ranitidine tablets in 150mg and 300mg strengths. This approval marks the re-entry of this important acid-reducing medication into the US market after a five-year absence.

The approval by the US FDA comes after extensive safety testing and manufacturing improvements that address previous concerns regarding the formation of NDMA impurity. It is expected to increase patient access to this important medication for patients who rely on it for various health conditions.

SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specialising in API and intermediates for global customers.